4DMEDICAL Ltd (ASX:4DX) rose 3.21% as of 11:10am AEST on 7 July 2026, with shares at $4.50. The move has drawn investor attention to the stock amid broader market activity on the ASX. For investors evaluating 4DMEDICAL Ltd, understanding the company's business model, the drivers behind today's share price movement and the key risks and opportunities ahead provides an essential foundation for making an informed assessment.

Company Overview

4DMEDICAL Ltd is an Australian medical technology company that has developed XV Technology — a proprietary software platform that uses standard MRI or CT scanners to produce four-dimensional functional images of lung ventilation. Unlike conventional anatomical imaging that shows what lungs look like, XV Technology shows how air moves through the lungs — revealing functional abnormalities invisible to traditional scans. The company targets applications in COPD, asthma, interstitial lung disease and post-COVID assessment, with a particular focus on the US Veterans Affairs health system and major hospital networks.

Business at a Glance

4DMEDICAL trades on the Australian Securities Exchange under the ticker ASX:4DX. The company is progressing commercial adoption of XV Technology in the United States through hospital and VA partnerships.

• XV Technology — functional lung imaging using standard MRI or CT equipment

• COPD and asthma assessment — revealing ventilation dysfunction

• Post-COVID lung assessment — identifying long COVID lung complications

• US Veterans Affairs — key commercial partner for functional lung imaging

• FDA clearance — regulatory approval for clinical use in the US

Strategic Positioning

4DMEDICAL's commercial strategy is centred on establishing XV Technology as a standard tool in respiratory medicine through clinical evidence generation, publication activity and commercial partnerships with hospital networks and the VA system. The company is pursuing a SaaS-based revenue model where hospitals pay a per-scan fee for access to XV Technology, creating recurring revenue as clinical adoption grows.

Recent Market Context

Respiratory disease is one of the world's largest disease burdens, with COPD alone affecting hundreds of millions globally. Post-COVID lung complications have raised clinical awareness of functional lung assessment beyond what structural imaging can reveal. 4DMEDICAL's commercial traction — particularly through the VA partnership — has been a key investor focus as the company works to demonstrate that XV Technology can achieve broad clinical adoption beyond early-stage partnerships.

Why Investors May Be Watching 4DMEDICAL Ltd

4DMEDICAL is followed by investors tracking medical imaging technology companies. VA partnership expansion, new hospital system adoption, clinical publication activity and the transition from pilot to commercial billing are key milestones investors monitor. The intraday gain of more than 3% may reflect positive news on commercial adoption, clinical evidence publication or other catalysts that have attracted renewed investor interest.

The Medical Imaging Software — Lung Function Industry

Medical imaging software for functional assessment is a growing segment as clinicians increasingly seek information beyond anatomical imaging. The ability to assess organ function — how well something works, not just what it looks like — using existing scanning equipment is a compelling clinical and economic proposition for hospitals. Respiratory disease management is becoming more sophisticated, with growing demand for tools that can better characterise disease severity and guide treatment decisions.

Where 4DMEDICAL Ltd Fits Within the Sector

4DMEDICAL occupies a specific and differentiated position in the medical imaging software sector, with a proprietary functional lung imaging capability that is genuinely novel. Its VA partnership provides a significant and credible early commercial reference.

Key Catalysts Investors May Monitor

Investors following 4DMEDICAL Ltd may monitor several developments:

• VA partnership expansion — growing number of participating facilities

• New hospital system commercial agreements

• Clinical study publications demonstrating XV Technology clinical utility

• Reimbursement pathway development for functional lung imaging

• FDA clearance for additional indications

• Half-year and full-year results and revenue growth

• Post-COVID lung assessment market development

• Technology integration with hospital imaging systems

Key Risks and Uncertainties

4DMEDICAL is an early commercial-stage company where revenue growth from a small base can be variable. Hospital technology adoption requires clinical evidence, workflow integration and budget approval — creating extended sales cycles. Reimbursement pathway development is a critical but uncertain process. The company requires ongoing capital to fund operations during the commercial ramp-up phase.

Balanced Outlook

4DMEDICAL's near-term commercial progress will be measured through VA facility expansion, new hospital adoptions and the development of a reimbursement pathway that allows broader clinical billing. Positive clinical publications are important for driving physician awareness and adoption. Longer-term, if XV Technology achieves broad clinical adoption as a standard respiratory assessment tool, the addressable market across COPD, asthma and post-COVID patients is substantial.

Considerations That May Support Interest

• Proprietary functional lung imaging addressing genuine clinical gap in respiratory assessment

• US Veterans Affairs partnership providing credible large-scale commercial reference

• Applications across COPD, asthma, interstitial lung disease and post-COVID

• FDA clearance providing US market access for clinical deployment

• Per-scan SaaS model creating scalable recurring revenue as adoption grows

Considerations That Warrant Caution

• Early commercial stage with revenue growing from a small base

• Hospital adoption cycles are long and require clinical evidence and budget approval

• Reimbursement pathway development is critical but uncertain

• Ongoing capital requirements during commercial ramp-up phase

• Clinical publication volume needs to build to drive physician awareness

Conclusion

4DMEDICAL's 3%-plus intraday gain on 7 July 2026 reflects periods of investor optimism about this lung imaging technology company's commercial progress. The clinical rationale for functional lung imaging is compelling — providing information about how lungs work that no existing imaging technology offers — and the VA partnership provides a credible commercial foundation. For investors evaluating 4DMEDICAL, the key questions are the pace of hospital commercial adoption beyond the VA, the development of a reimbursement pathway that enables broader clinical billing, and whether the clinical evidence base is building quickly enough to drive the physician adoption that commercial success requires. Those with conviction in the clinical utility of functional lung imaging and patience for a medical technology commercial ramp will find 4DMEDICAL's XV Technology a genuinely differentiated proposition.